Efficacy and Safety Study of the Use of Benralizumab for Patients With Moderate to Severe Atopic Dermatitis

NCT04605094 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

194

Enrollment

INDUSTRY

Sponsor class

Stopped The study did not meet the primary endpoint.

Conditions

Atopic Dermatitis

Interventions

BIOLOGICAL: Benralizumab
BIOLOGICAL: Placebo / Benralizumab

Sponsor

AstraZeneca

Collaborators

[object Object]